Craniofacial Resection for Advanced Cutaneous Squamous Cell Carcinoma: Results From the 2nd International Collaborative Case-Series.

Authors

Michael J C Schachtel, Benedict J Panizza, James J Bowman, Catherine Barnett, Cristina Valero, Ian Ganly, Snehal G Patel, Helena Levyn, Dauren Adilbay, Alana Eagan, Marc A Cohen, Lillian A Boe, Junting Zheng, Mithat Gonen, Prathamesh Pai, Paolo Castelnuovo, Fang Ju Gao, Cesare Piazza, Piero Nicolai, Luiz P Kowalski, Ronaldo N Toledo, Claudio Cernea, Sergio Goncalves, Dan M Fliss, John R de Almeida, Ian Witterick, Philippe Herman, Walter Fontanella, Gregorio Sanchez Aniceto, Alvaro Rivero Calle, Sefik Hosal, Serdar Ozer, Subramania Iyer, Richard J Harvey, C Rene Leemans, Jan-Jaap Hendrickx, Marcelo Figari, Luis Boccalatte, Ken Ichi Nibu, Peter Clarke, Catherine Rennie, Yiming Zhu, Rodney J Schlosser, Fernando L Dias, Zoukaa Sargi, Shahzada Ahmed, Wojciech Golusinski, Se Heon Kim, Shirley Y Su, Shaan M Raza, Franco DeMonte, Ehab Hanna, Jatin P Shah

Published in

Head & neck. Jul 27, 2026. Epub Jul 27, 2026.

Abstract

Robust outcome data for anterior skull base cutaneous squamous cell carcinoma (cSCC) are limited, particularly as emerging therapies reshape management. We evaluated survival and prognostic factors following craniofacial resection.
Retrospective multi-institutional case-series (1995-2015) of patients who underwent skull base surgery for anterior face/scalp cSCC. Kaplan-Meier and Cox regression analyses assessed disease-free (DFS), disease-specific (DSS), and overall survival (OS).
Among 112 patients, most had T4 (86.6%) and recurrent (71.4%) disease. Clear margins were achieved in 32.1%; 40.2% were involved. Five-year DFS, DSS, and OS were 46.9%, 68.4%, and 52.3%, respectively. Intracranial extension independently predicted worse OS (HR:6.54 [95% CI:2.61,16.38]) and DSS (HR:12.39 [95% CI:2.72,56.45]). Involved margins predicted recurrence on univariable analysis. Adjuvant therapy, predominantly post-operative radiotherapy, improved OS (HR: 0.54 [95% CI: 0.30,0.97]). Complications occurred in 38.4%, with 4.5% perioperative mortality.
Advanced anterior skull base cSCC carries substantial morbidity and modest survival. These data provide a benchmark against which immunotherapy-based strategies should be evaluated.

PMID:
42509203
Bibliographic data and abstract were imported from PubMed on 28 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.